



Procedure	Result	Units	Ref Interval	Accession	Collected	Received	Reported/Verified
HLA Class I-Locus A*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus A*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus B*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus B*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus Bw*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus Bw*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus C*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I-Locus C*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DRB1*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DRB1*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DRB3*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DRB3*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DRB4*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DRB4*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DRB5*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DRB5*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DQA1*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DQA1*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DQB1*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DQB1*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DPA1*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DPA1*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DPB1*, Allele 1	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class II-Locus DPB1*, Allele 2	SEE NOTE @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
HLA Class I and Class II Loci 11 Interp	See Note @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20
EER HLA Class I and Class II Loci 11	See Note @			20-084-900237	24-Mar-20	24-Mar-20	24-Mar-20

24-Mar-20 15:14:00 HLA Class I-Locus C*, Allele 1,HLA Class I-Locus A*, Allele 1,HLA Class II-Locus DRB5*, Allele 2,HLA Class I-Locus Bw*, Allele 2,HLA Class I and Class II Loci 11 Interp,HLA Class I-Locus A*, Allele 2,HLA Class II-Locus DRB4*, Allele 2,HLA Class I-Locus C*, Allele 2,HLA Class II-Locus DPB1*, Allele 1,HLA Class II-Locus DPA1*, Allele 2,HLA Class II-Locus DQA1*, Allele 1,HLA Class II-Locus DRB1*, Allele 1,HLA Class II-Locus DQB1*, Allele 1,HLA Class II-Locus DRB3*, Allele 2,HLA Class I-Locus B*, Allele 1,EER HLA Class I and Class II Loci 11,HLA Class II-Locus DQB1*, Allele 2,HLA Class II-Locus DRB3*, Allele 1,HLA Class I-Locus Bw*, Allele 1,HLA Class II-Locus DRB4*, Allele 1,HLA Class I-Locus B*, Allele 2,HLA Class II-Locus DRB5*, Allele 1,HLA Class II-Locus DRB1*, Allele 2,HLA Class II-Locus DPB1*, Allele 2,HLA Class II-Locus DPA1*, Allele 1,HLA Class II-Locus DQA1*, Allele 2:
 Performed at: UUHC: Histocompatibility and Immunogenetics, 417 Wakara Way, Ste. 3220, SLC, UT 84108

24-Mar-20 15:14:00 HLA Class I and Class II Loci 11 Interp:

INTERPRETIVE INFORMATION: HLA Class I and II 11 Loci Panel

NGS

Purpose: To identify HLA-A, -B, -C, -DRB1, -DRB345, -DQA1, -DQB1, -DPA1, and -DPB1 allelic polymorphisms on specimens for transplant candidates and their donors.

Methodology: PCR followed by next generation sequencing of HLA-A, -B, -C, -DRB1, -DRB345, -DQA1, -DQB1, -DPA1 and -DPB1 loci.

Analytical Sensitivity & Specificity: >99 percent.

Limitations: Rare diagnostic errors can occur due to primer site mutations.

Test Results: Results are reported as HLA locus (A, B, C, DRB1, DRB345, DQA1, DQB1, DPA1, DPB1)* followed by the two-field (four digit) assigned allele.

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab

Disclaimer Information:

HLA typing is performed by one or more of the following methodologies: next generation sequencing (NGS) and/or sequence specific probe hybridization (SSOP). The NMDP code provides possible rare alleles that cannot be ruled out. Additional unknown DNA polymorphisms could exist outside of the regions analyzed, the significance of which is not known.

This test was developed and its performance characteristics determined by the Histocompatibility& Immunogenetics laboratory at the University of Utah Health, and has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes; it should not be regarded as investigational or for research. The University of Utah Histocompatibility& Immunogenetics laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to perform high complexity clinical laboratory testing. Performed at: Histocompatibility& Immunogenetics laboratory, University of Utah Health, 417 Wakara Way, Suite 3220, Salt Lake City, UT 84108.